ArticleNature2023
Neoantigen-targeted CD8
Open access · greenAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 1 pooled it
48.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 1 synthesis or guideline pooled it, 192 citations in OpenAlex.
- Global research trends and focus on biomarkers in lung cancer immunotherapy: a comprehensive bibliometric insight and visualization analysis (2001-2025).Frontiers in immunology · 2026Pooled it
- HLA-II Expression Marks Activated and Clonally Expanded CD8International journal of molecular sciences · 2026Article
- Review
- Current landscape and future directions of neoantigen vaccines: A new era of personalized cancer immunotherapy.Innovation (Cambridge (Mass.)) · 2026Review
- Cancer Vaccine Development: Toward Artificial Intelligence-Assisted Personalized Cell Membrane Nanovaccine.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- The Central Role of HLA Class II-Restricted Helper Neoantigen Vaccines in Cancer Immunotherapy.Cancers · 2026Review
- Nonsense-mediated mRNA decay as a gatekeeper of neoantigen expression: Bridging RNA surveillance and tumor immunotherapy.Molecular biology reports · 2026Review
- Breaking the bottleneck of asthma treatment: the future of omni-targeted therapy.Journal of advanced research · 2026Review
- Hallmarks and correlates of effective adoptive cell immunotherapy for cancer.Nature reviews. Immunology · 2026Review
- Preexisting TCR Clones Drive Major Pathologic Responses in Patients with HNSCC Treated with Dual Immune Checkpoint Inhibitors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Whole-protein screening and multi-modal profiling of antigen-specific CD4Nature communications · 2026Article
- Bright side of the dark genome: antigens for next-gen cancer vaccines.Journal for immunotherapy of cancer · 2026Review
- Molecular origin, discovery, validation and application of neoantigens.Asian journal of pharmaceutical sciences · 2026Review
- Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy.Nature biomedical engineering · 2026Article
- T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy.Cancer immunology research · 2026Article
- TCR sequencing in cancer immunology and immunotherapy: what, when, where, why, and how.Journal for immunotherapy of cancer · 2026Review
- A Framework for Comparing Mouse Neoantigen Immunogenicity.bioRxiv : the preprint server for biology · 2026Article
- Circulating Neoantigen- and Viral Oncoprotein-Specific CD8+ T Cells Share a Transcriptional Signature.Cancer immunology research · 2026Article
- T cell immunotherapy for solid tumors: limitations, progress, and future prospects.Frontiers in immunology · 2026Review
- CX3CR1 identifies a potent effector CD8Frontiers in immunology · 2026Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
56 authors at 5 institutions in 3 countries.
Cristina Puig-SausDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA. cpuigsaus@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-3014-3649
Barbara SenninoPACT Pharma, San Francisco, CA, USA.
Songming PengPACT Pharma, San Francisco, CA, USA.
Clifford L WangPACT Pharma, San Francisco, CA, USA.
Zheng PanPACT Pharma, San Francisco, CA, USA.
Benjamin YuenPACT Pharma, San Francisco, CA, USA.
Bhamini PurandarePACT Pharma, San Francisco, CA, USA.
Duo AnPACT Pharma, San Francisco, CA, USA.
Boi B QuachPACT Pharma, San Francisco, CA, USA.
Diana NguyenPACT Pharma, San Francisco, CA, USA.
Huiming XiaMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0003-2571-1880
Sameeha JilaniDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Kevin ShaoPACT Pharma, San Francisco, CA, USA.
Claire McHughPACT Pharma, San Francisco, CA, USA.
John GreerPACT Pharma, San Francisco, CA, USA.
Phillip PeabodyPACT Pharma, San Francisco, CA, USA.
Saparya NayakPACT Pharma, San Francisco, CA, USA.
Jonathan HooverPACT Pharma, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-2893-4425
Sara SaidPACT Pharma, San Francisco, CA, USA.
Kyle JacobyPACT Pharma, San Francisco, CA, USA.
Olivier DalmasPACT Pharma, San Francisco, CA, USA.
Susan P FoyPACT Pharma, San Francisco, CA, USA.
Andrew ConroyPACT Pharma, San Francisco, CA, USA.
Michael C YiPACT Pharma, San Francisco, CA, USA.
Christine ShiehPACT Pharma, San Francisco, CA, USA.
William LuPACT Pharma, San Francisco, CA, USA.
Katharine HeeringaPACT Pharma, San Francisco, CA, USA.
Yan MaPACT Pharma, San Francisco, CA, USA.
Shahab ChizariPACT Pharma, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5659-1140
Melissa J PillingPACT Pharma, San Francisco, CA, USA.
Marc TingPACT Pharma, San Francisco, CA, USA.
Ramya TunuguntlaPACT Pharma, San Francisco, CA, USA.
Salemiz SandovalPACT Pharma, San Francisco, CA, USA.
Robert MootPACT Pharma, San Francisco, CA, USA.
Theresa HunterPACT Pharma, San Francisco, CA, USA.
Sidi ZhaoMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO, USA.
Justin D SacoDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Ivan Perez-GarcilazoDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Egmidio MedinaDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Agustin Vega-CrespoDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Ignacio Baselga-CarreteroDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Gabriel Abril-RodriguezDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Grace CherryDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Deborah J WongDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Jasreet HundalMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO, USA.
Bartosz ChmielowskiDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2374-3320
Daniel E SpeiserDepartment of Oncology, University of Lausanne, Lausanne, Switzerland.
Michael T BethunePACT Pharma, San Francisco, CA, USA.
Xiaoyan R BaoPACT Pharma, San Francisco, CA, USA.
Alena GrosVall d'Hebron Institute of Oncology, Barcelona, Spain.ORCID http://orcid.org/0000-0002-1207-1880
Obi L GriffithMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-0843-4271
Malachi GriffithMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-6388-446X
James R HeathInstitute for Systems Biology, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-5356-4385
Alex FranzusoffPACT Pharma, San Francisco, CA, USA.
Stefanie J Mandl *PACT Pharma, San Francisco, CA, USA.
Antoni Ribas *Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-3669-8458
University of California, Los Angeles · USJames S. McDonnell Foundation · USInstitute for Systems Biology · USUniversity of Lausanne · CHVall d'Hebron Institute of Oncology · ES
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MProject 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2020 to 2024
$12.8MWashington University SPORE in Pancreatic CancerP50CA272213 · NCI · WASHINGTON UNIVERSITY · PI David G DeNardo, WILLIAM G HAWKINS · 2023 to 2026
$10.7MNext Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4MUCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3MNCI NIH HHS P01 CA244118NCI NIH HHS P30 CA016042NCI NIH HHS P30CA016042NCI NIH HHS P50 CA272213NCI NIH HHS R35 CA197633NCI NIH HHS T32 CA009120
Abstract
Neoantigens are peptides derived from non-synonymous mutations presented by human leukocyte antigens (HLAs), which are recognized by antitumour T cells
Indexed as
Antigens, NeoplasmCD8-Positive T-LymphocytesImmune Checkpoint InhibitorsImmunotherapyMelanomaCRISPR-Cas SystemsGene EditingHLA AntigensHumansMutationNeoplasm MetastasisPrecision MedicineProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellAntigens, NeoplasmHLA AntigensImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.